177 related articles for article (PubMed ID: 9205749)
1. Metabolism of ebrotidine. A review.
Rozman E; Albet C; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):486-9. PubMed ID: 9205749
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical properties, analytical determinations and stability of ebrotidine.
Albet C; Fernández JM; Castelló JM; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):435-8. PubMed ID: 9205739
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the metabolism of ebrotidine in human urine by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
Rozman E; Galceran MT; Anglada L; Albet C
Drug Metab Dispos; 1995 Sep; 23(9):976-81. PubMed ID: 8565788
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
[TBL] [Abstract][Full Text] [Related]
6. Metabolites of ebrotidine, a new H2-receptor antagonist, in human urine.
Rozman E; Galcerán MT; Anglada L; Albet C
J Pharm Sci; 1994 Feb; 83(2):252-4. PubMed ID: 7909553
[TBL] [Abstract][Full Text] [Related]
7. Determination of ebrotidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography.
Rozman E; Galcerán MT; Albet C
J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(1):107-15. PubMed ID: 9029320
[TBL] [Abstract][Full Text] [Related]
8. Ebrotidine and its metabolites studied by mass spectrometry with electrospray ionization. Comparison of tandem and in-source fragmentation..
Rozman E; Galcerán MT; Albet C
Rapid Commun Mass Spectrom; 1995; 9(15):1492-8. PubMed ID: 8652876
[TBL] [Abstract][Full Text] [Related]
9. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Muñoz-Navas M; Honorato J; Reina-Ariño M; Márquez M; Herrero E; Villamayor F; Torres J; Roset PN; Fíllat O; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
[TBL] [Abstract][Full Text] [Related]
11. Determination of ebrotidine and its metabolites by capillary electrophoresis with UV and mass spectrometry detection.
Sentellas S; Puignou L; Moyano E; Galceran MT
J Chromatogr A; 2000 Aug; 888(1-2):281-92. PubMed ID: 10949494
[TBL] [Abstract][Full Text] [Related]
12. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
Gabryelewicz A; Czajkowski A; Skrodzka D; Marlicz K; Luca de Tena F; Aldeguer M; Chantar C; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
[TBL] [Abstract][Full Text] [Related]
14. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
15. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
16. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Gedliczka O; Bobrzynski A; Rembiasz K; Fillat O; Torres J; Herrero E; Márquez M; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
[TBL] [Abstract][Full Text] [Related]
18. Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
Agut J; Sánchez JC; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):447-9. PubMed ID: 9205741
[TBL] [Abstract][Full Text] [Related]
19. Determination of ebrotidine and its metabolites by micellar electrokinetic capillary chromatography.
Sentellas S; Puignou L; Galceran MT
J Chromatogr A; 2002 Nov; 976(1-2):221-7. PubMed ID: 12462613
[TBL] [Abstract][Full Text] [Related]
20. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
Tulassay Z; Döbrönte Z; Farkas I; Juhász L; Simon L; Prónai L; Torres J; Márquez M
Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
